Drug Approval | June 14, 2022
FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
The production suspension impacts commercial and clinical trial supply
CIVCO RT will also display its recent innovations focusing on improving patient comfort and outcomes
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
Subscribe To Our Newsletter & Stay Updated
